



UBAM - SWISS EQUITY

Quarterly Comment | Q3 2019

For Qualified Investors in Switzerland or Professional Investors or Eligible Counterparties as defined by the relevant laws.

Market Comment

- ◆ September marked the end of a mixed quarter for equity markets with the MSCI AC World finishing Q3 2019 flat at -0.03%. Major indices delivered positive performances over the quarter except Emerging Markets equities which were down -4.3%. Japanese and European equities posted the biggest gains with +3.3% and +2.6%, most of which recorded over the month of September; followed by Swiss equities with +2.1%, US equities +1.7%. The SPI Extra also posted gains with +1% over the quarter. Year to date, Swiss equities continue to outperform with +24.4% versus close to +16% for global equities.
- ◆ In September, major central banks steered further easing measures following a second setback in equity markets that came in August after that of May. Major economies progressed into late cycle stages with a synchronized deceleration in industrial production and stabilising inflation in labor and commodities markets. The US Federal Reserve cut interest rates by 25bps in mid-September for the second time in 2019, leaving the door open for another cut if needed before the end of the year. This came after the ECB also cut its key interest rate down to -0.5% with plans to restart quantitative easing in November. September was notably marked by a sector/style rotation into oversold value names that proved to be short lived, as it was not supported by EPS growth expectations. In fact, cyclical sectors, commodity related and financials, posted the biggest negative earnings revisions for 2019. Despite the convergence of 2019 earnings growth expectations for global equities to low single digit (2% for 2019 versus 10% for 2020), valuation levels remained around their long term averages. With a 3% dividend yield, global equities could still deliver 5% of total return for 2019 on unchanged multiples.
- ◆ Early September, despite a strong Swiss Franc, the Swiss National Bank kept rates unchanged at -0.75% while reiterating its willingness to intervene in the FX market as necessary. Swiss GDP expectations for the year 2019 have been lowered by the SNB to a 1%-1.5% range; inflation was also revised lower from 0.6% to 0.4% for the year. Trade balance came in weaker for the end of August as trade war worries and a strong currency pressured Swiss exports. The unemployment rate for Switzerland remained low and stable at 2.3% at end of August, with inflation flat at 0%. PMI prints rebounded to 47.2 at end of August on improved business sentiment vs. 44.7 in July, but dipped down to 44.7 for end of September. The KOF leading indicator fell however by 2.3 points to 93.2, highlighting weaker industrial production despite a resilient consumer confidence.
- ◆ Over the third quarter of 2019, the SPI saw a sharp reversal of performance in cyclical sectors with Consumer Discretionary, Industrials and Materials losing -7.7% -1.3% and -1.8% respectively (-35bps; -16bps and -11bps of respective contribution to the SPI). Defensive sectors on the other hand continued performing strongly with Consumer Staples contributing to +1.64% to the overall performance of the index, and Nestlé alone contributing to +1.62%. Financials and Healthcare were also positive performers with +0.6% and +0.3% in respective contribution to the overall performance.

Performance Review

- ◆ Over the third quarter of 2019, the fund returned +2.2% in gross performance versus +2.1% for the SPI. Year to date, the fund has accumulated close to +26.1% in gross performance with +1.6% in excess return. Stock selection contributed positively over the quarter with +26bps, which was slightly offset by sector allocation with -19bps. Consumer Staples was in fact the most detracting sector with -77bps, mainly due to the forced underweight of Nestlé in the fund. Stock selection in the Financials and Health Care sectors contributed the most over the quarter with +40bps, +22bps respectively.
- ◆ In terms of individual names, the best contributors on the portfolio level over Q3 2019 were the underweight in Novartis which lost -3% over the quarter (+38ps contribution), the absence of exposure to Richemont which lost close to -10% (+34bps) and the overweight in Zurich Insurance Group (+21bps). Despite publishing a strong set of Q2 results and a positive guidance for the full year, Novartis share price struggled to keep up with the overall market following the FDA's accusation of manipulation of test data for the approval of the gene therapy Zolgensma. Richemont's share price faltered over the quarter as Swiss watch exports dropped more than 10% on concerns ensuing from protests paralyzing Hong Kong, a key luxury market. Zurich Insurance's share price increased by more than 12% over Q3 as it reported a strong 16% increase in operating income for the first half of the year, and looked set to meet its targets for its three-year program focused on cost savings.
- ◆ The biggest relative detractors over Q3 were the forced underweight in Nestlé, which was up 7% (-62bps) as well as Roche (up 5%, -15bps), and the overweight in Sika (-35bps). Nestlé continued its rally with more than 39% return YTD, especially after beating consensus estimates with 3.9% reported organic sales growth for Q2. The company also improved its profitability, on track for its 2020 targets and confirmed its outlook for the full year. September put a halt to this rally as the name corrected down by almost 2.5%. Roche reported the EU Commission's approval on the Tecentriq combination therapy for the treatment of breast cancer, and further confirmed its ability to maintain growth through patents with new products representing 20% of sales. Sika on the other hand had a weak performance over the quarter with -12% drop in share price after reporting modest Q2 organic growth results offset by positive M&A impact. The team still holds a positive view on the name as new countries and Emerging Markets penetration still offer positive prospects for organic growth.

Portfolio Activity

- ◆ During the month of July, the position in SGS was exited and the proceeds were reinvested in the existing position in Alcon. On the back of a weak performance since Q1 19 coupled with high valuation and on-going earnings downgrades, the team decided to cut the exposure to the industrial company. The position in Alcon was reinforced as the name is showing resilience to the economic and political backdrop. A position in Interroll was initiated following the publication of their 1H19 results. The expected slowdown in the second half of 2019 is not seen as an issue by the team based on the company's record year last year and the resilience of long term fundamentals.
- ◆ During the month of August, the team took some profits in Partners Group after solid YTD performance, and reinforced its position in Vifor after strong reported results and positive guidance with good growth momentum.
- ◆ No major changes were done on the portfolio level during the month of September.

Outlook

- ◆ After a flat third quarter, the team expects equity markets to continue moving sideways for the rest of the year, with volatility swings coupled with geopolitical developments as trade remains a major topic. Despite downside risks on the political front and trade developments, consumer confidence is still resilient on stable inflation and labor conditions. An active management approach should offer equity investors a diversified exposure to proven high quality and growth names without the need to time style factors in this late cycle phase. Furthermore, as the Swiss market does not have any direct exposure to Energy and Metals & Mining stocks where the 2020 earnings' rebound is at risk, Swiss equities still offer one of the highest and most stable earnings growth (around 8% for 2019 and 9.6% for 2020). Coupled with 3% dividend yield, Swiss equities should still deliver 11% total return for 2019 on unchanged multiples.

Disclaimer

This is a marketing document and is intended for informational and/or marketing purposes only. This document is confidential and is intended only for the use of the person(s) to whom it was delivered. This document may not be reproduced (in whole or in part) or delivered, given, sent or in any other way made accessible, to any other person without the prior written approval of Union Bancaire Privée, UBP SA or any entity of the UBP Group ("UBP"). This document reflects the opinion of UBP as of the date of issue.

This document is for distribution only to persons who are Qualified Investors in Switzerland or Professional Clients, Eligible Counterparties or equivalent category of investors as defined by the relevant laws (all such persons together being referred to as "relevant persons"). This document is directed only at relevant persons and must not be acted on or relied on by persons who are not relevant persons. It is not intended for distribution, publication, or use, in whole or in part, in any jurisdiction where such distribution, publication, or use would be unlawful, nor is it directed to any person or entity to which it would be unlawful to direct such a document. In particular, this document may not be distributed in the United States of America and/or to US Persons (including US citizens residing outside the United States of America).

This document has not been produced by UBP's financial analysts and is not to be considered as financial research. It is not subject to any guidelines on financial research and independence of financial analysis.

Reasonable efforts have been made to ensure that the content of this document is based on information and data obtained from reliable sources. However, UBP has not verified the information from third sources in this document and does not guarantee its accuracy or completeness. UBP accepts no liability whatsoever and makes no representation, warranty or undertaking, express or implied, for any information, projections or any of the opinions contained herein or for any errors, omissions or misstatements. The information contained herein is subject to change without prior notice. UBP gives no undertaking to update this document or to correct any inaccuracies in it which may become apparent.

This document may refer to the past performance of investment interests. **Past performance is not a guide to current or future results.** The value of investment interests can fall as well as rise. Any capital invested may be at risk and you may not get back some or all of your original capital. In addition, any performance data included in this document does not take into account fees and expenses charged on issuance and redemption of securities nor any taxes that may be levied. Changes in exchange rates may cause increases or decreases in your return.

All statements other than statements of historical fact in this document are "forward-looking statements". Forward-looking statements are not guarantees of future performance. The financial projections included in this document do not represent forecasts or budgets, but are purely illustrative examples based on a series of current expectations and assumptions which may not eventuate. The actual performance, results, financial condition and prospects of an investment interest may differ materially from those expressed or implied by the forward-looking statements in this document as the projected or targeted returns are inherently subject to significant economic, market and other uncertainties that may adversely affect performance. UBP disclaims any obligation to update any forward-looking statement, as a result of new information, future events or otherwise.

It should not be construed as advice or any form of recommendation to purchase or sell any security or funds. It does not replace a prospectus or any other legal documents that can be obtained free of charge from the registered office of a fund or from UBP. The opinions herein do not take into account individual investors' circumstances, objectives, or needs. Each investor must make his/her own independent decision regarding any securities or financial instruments mentioned herein and should independently determine the merits or suitability of any investment. In addition, the tax treatment of any investment in the fund(s) mentioned herein depends on each individual investor's circumstances. Investors are invited to read carefully the risk warnings and the regulations set out in the prospectus or other legal documents and are advised to seek professional advice from their financial, legal and tax advisors. The tax treatment of any investment in the Fund depends on your individual circumstances and may be subject to change in the future.

The document neither constitutes an offer nor a solicitation to buy, subscribe for or sell any currency, funds, product or financial instrument, make any investment, or participate in any particular trading strategy in any jurisdiction where such an offer or solicitation would not be authorised, or to any person to whom it would be unlawful to make such an offer or invitation.

Telephone calls to the telephone number stated in this presentation may be recorded. When calling this number, UBP will assume that you consent to this recording.

UBP is authorised and regulated in Switzerland by the Swiss Financial Market Supervisory Authority and is authorised in the United Kingdom by the Prudential Regulation Authority. UBP is subject to regulation by the Financial Conduct Authority and limited regulation by the Prudential Regulation Authority.

Any subscriptions not based on the funds' latest prospectuses, KIID, annual or semi-annual reports or other relevant legal document shall not be acceptable. The latest prospectus, articles of association, KIID and annual and semi-annual reports of the funds presented herein (the "Funds' Legal Documents") may be obtained free of charge from Union Bancaire Privée, UBP SA, 96-98, rue du Rhône, P.O. Box 1320, 1211 Geneva 1 ("UBP"). The Funds' Legal Documents may also be obtained free of charge from UBP Asset Management (Europe) S.A., 287-289 route d'Arion, 1150 Luxembourg, Grand Duchy of Luxembourg. The Funds' Legal Documents may also be obtained free of charge from Union Bancaire Gestion Institutionnelle (France) SAS, 127, avenue des Champs-Élysées, 75008 Paris, France.